Thyroid Diseases  >>  Caprelsa (vandetanib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Caprelsa (vandetanib) / Sanofi
NCT00358956 / 2006-001354-28: A Study To Assess ZD6474 (ZACTIMA™) Monotherapy In Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

Completed
2
19
US, Canada, Europe, RoW
ZD6474 (vandetanib), Caprelsa™
Genzyme, a Sanofi Company
Thyroid Cancer
01/08
05/14
NCT00098345: Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer

Completed
2
40
US, Europe
ZD6474 (vandetanib), Caprelsa™ (vandetanib), SAR390530
Genzyme, a Sanofi Company
Thyroid Cancer
02/08
04/17
NCT01661179: Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma

Completed
1/2
14
Japan
Vandetanib 300mg, ZD6474
Genzyme, a Sanofi Company
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
12/13
07/14
NCT00923247: A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Checkmark P1 Data
May 2011 - May 2011: P1 Data
Terminated
1/2
22
US
Bortezomib, Velcade, Vandetanib, Caprelsa
National Cancer Institute (NCI)
Medullary Thyroid Carcinoma
04/16
12/16

Download Options